New eczema drug enters first human testing phase
NCT ID NCT07358156
Summary
This early-stage study aims to understand how a new potential drug for atopic dermatitis (eczema), called CKD-706, behaves in the body compared to two versions of an existing drug, Dupixent. It involves 519 healthy adult volunteers who will receive a single dose. Researchers will primarily track how long the drug stays in the blood and how the body reacts to it over 85 days to see if the new drug performs similarly.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Parexel EPCU Berlin
NOT_YET_RECRUITINGBerlin, State of Berlin, 10115, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Parexel EPCU London
RECRUITINGLondon, England, HA1 3UJ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.